Albion Financial Group UT Trims Stake in Amgen Inc. $AMGN

Albion Financial Group UT reduced its position in Amgen Inc. (NASDAQ:AMGN) by 8.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,281 shares of the medical research company’s stock after selling 2,357 shares during the quarter. Albion Financial Group UT’s holdings in Amgen were worth $7,948,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Brighton Jones LLC raised its position in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the period. Sivia Capital Partners LLC raised its position in Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the period. Schnieders Capital Management LLC. raised its position in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares during the period. Kennedy Capital Management LLC raised its position in Amgen by 4.4% in the 2nd quarter. Kennedy Capital Management LLC now owns 2,835 shares of the medical research company’s stock worth $792,000 after purchasing an additional 119 shares during the period. Finally, Jump Financial LLC raised its position in Amgen by 1,449.7% in the 2nd quarter. Jump Financial LLC now owns 23,432 shares of the medical research company’s stock worth $6,542,000 after purchasing an additional 21,920 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a research report on Tuesday, January 20th. Rothschild & Co Redburn raised their target price on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Barclays assumed coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. Argus raised their target price on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Cantor Fitzgerald raised their target price on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Price Performance

Shares of AMGN opened at $342.57 on Tuesday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a 50 day moving average of $363.51 and a two-hundred day moving average of $333.65. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a market cap of $184.67 billion, a price-to-earnings ratio of 24.07, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.